Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study
Kristina Jenei(London School of Economics and Political Science), Bishal Gyawali(Ontario Institute for Cancer Research), Dario Trapani(Harvard University), Karin Berger(Ludwig-Maximilians-Universität München), Kazunori Honda(Aichi Cancer Center), Arnaud Bayle(Inserm), Deme Karikios(The University of Sydney), Adam Raymakers(Brigham and Women's Hospital), Scott Berry(Queen's University), Christopher C G A Jackson(University of Otago), Avi Cherla(London School of Economics and Political Science)
Cited by 48
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818